Ibrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemia

Basit Öğe Kaydı
dc.contributor.authorKorkmaz, Mustafa
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorAraz, Murat
dc.contributor.authorCeneli, Ozcan
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T14:21:05Z
dc.date.available2024-02-23T14:21:05Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractIbrutinib is a Bruton tyrosine kinase inhibitor used in the treatment of chronic lymphocytic leukemia (CLL). Panitumumab, an mAb for epidermal growth factor receptor, is used in the treatment of metastatic colorectal cancer (CRC). We wanted to present our case where we used ibrutinib and panitumumab in combination in a patient with metachronous CLL and CRC. A 58-year-old male patient with a diagnosis of CLL was receiving ibrutinib treatment and primary rectal cancer was detected. FOLFOX + panitumumab were started when metastasis was detected in the lung after neoadjuvant chemoradiotherapy for rectal cancer. The patients used ibrutinib and panitumumab in combination. There was no cumulative or unexpected toxicity due to the combination of both antineoplastic agents. The most important point to be considered in the use of combined drugs is the evaluation of drug-drug interactions. Toxic effects of the combination of ibrutinib and cetuximab have been reported in a patient with metastatic CRC. We used ibrutinib together with panitumumab in our case and we did not encounter any cumulative or unexpected side effects during the treatment.en_US
dc.identifier.doi10.1097/CAD.0000000000001333
dc.identifier.endpage767en_US
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue8en_US
dc.identifier.pmid35946528en_US
dc.identifier.scopus2-s2.0-85136856250en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage765en_US
dc.identifier.urihttps://doi.org/10.1097/CAD.0000000000001333
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13444
dc.identifier.volume33en_US
dc.identifier.wosWOS:000841282200009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIbrutiniben_US
dc.subjectPanitumumaben_US
dc.subjectChronic Lymphoid Leukemiaen_US
dc.subjectColorectal Canceren_US
dc.titleIbrutinib and panitumumab used in combination safely in a patient with metachronous colorectal cancer and chronic lymphocytic leukemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu